Biotech Company Orphazyme ApS today announces addition of new expertise to its Management Team and to its Board of Directors
1 March, 2013, Copenhagen, Denmark; Orphazyme is proud to present a significant strengthening of the Management and Board with the hire of Dr. Carlos Camozzi as new Chief Medical Officer (CMO) and the appointment of Dr. Georges Gemayel to the Board of Directors.
Dr. Camozzi brings extensive experience from more than 25 years in clinical research and development roles in pharma and biotech companies, including leading clinical operations in the rare disease area. Prior to joining Orphazyme ApS Dr. Camozzi was the VP-CMO of uniQure BV and before that a Medical Director and Head of Medical Affairs with Orphan Europe. Dr. Camozzi has a an MD and Ph.D. from the School of Medicine, National University of Buenos Aires (Argentina), and degrees in Paediatrics, Neonatology, Clinical Pharmacology and Neuropsychiatry.
Anders Hinsby, CEO of Orphazyme ApS, says: "We are very pleased that Dr. Carlos Camozzi has accepted the position as CMO; Carlos’ experience, particularly in the rare disease field, is an ideal match for Orphazyme, and we are happy that he joins us to lead our ambition of bringing the heat shock protein based programs successfully into and through clinical development."
Orphazyme welcomes Dr. Georges Gemayel to its Board of Directors. Dr. Gemayel is a seasoned pharmaceutical and biotechnology company executive, and currently serves as Chairman of the Board of Vascular Magnetics Inc., as well as on the Board of Directors of NPS Pharmaceuticals. He previously served as Executive Chairman of Syndexa Pharmaceuticals and of FoldRx Pharmaceuticals Inc., President and Chief Executive Officer of Altus Pharmaceuticals Inc., Executive Vice President of Genzyme Corporation, Vice President of Roche Specialty Care, and General Manager of Roche Portugal. Dr. Gemayel received his Doctorate in Pharmacy at Saint Joseph University in Beirut, Lebanon, and earned a Ph.D. in Pharmacology at Paris-Sud University in France.
Continues Anders Hinsby: "Welcoming Dr. Georges Gemayel to the Board of Directors is a great pleasure. Georges has extensive experience from more than 20 years in the pharmaceutical and biotech industry, and a profound understanding of Orphan product development and commercialisation. The appointments of Dr. Carlos Camozzi and Dr. Georges Gemayel bring additional experience and energy to Orphazyme as we head towards clinical studies in 2014."
Anders Hinsby, CEO of Orphazyme
Orphazyme ApS is a Danish biopharmaceutical company, which develops paradigm-changing medicines for the treatment of genetic diseases. The lead program is in preclinical development as treatment for lysosomal storage diseases. This family of genetic disorders consists of more than 45 diseases, most of which are currently untreatable and often fatal. Orphazyme has raised more than 17 million euro in seed and series A financing, from a strong investor base which includes Novo Ventures, Sunstone Capital and Aescap Venture. For more information, please visit www.orphazyme.com.